Mast Cells: Pivotal Players in Cardiovascular Diseases

Ilze Bot1,* Theo J.C. van Berkel1 and Erik A.L. Biessen1,2

1Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC, Leiden, The Netherlands, 2Pathology, University of Maastricht, P. Debeyelaan 25, 6202 AZ Maastricht, The Netherlands

Abstract: The clinical outcome of cardiovascular diseases as myocardial infarction and stroke are generally caused by rupture of an atherosclerotic plaque. However, the actual cause of a plaque to rupture is not yet established. Interestingly, pathology studies have shown an increased presence of the mast cell, an important inflammatory effector cell in allergy and host defense, in (peri)vascular tissue during plaque progression, which may point towards a causal role for mast cells. Very recent data in mouse models show that mast cells and derived mediators indeed can profoundly impact plaque progression, plaque stability and acute cardiovascular syndromes such as vascular aneurysm or myocardial infarction. In this review, we discuss recent evidence on the role of mast cells in the progression of cardiovascular disorders and give insight in the therapeutic potential of modulation of mast cell function in these processes to improve the resilience of a plaque to rupture.

Key Words: Cardiovascular diseases, atherosclerosis, mast cell, plaque stability, proteases, aneurysm.

1. INTRODUCTION

Already in 1876 during his thesis research Paul Ehrlich discovered a new, highly potent inflammatory cell type and designated it “mast cell”, after the basophilic storage granules [1-3]. Mast cells were found to respond to various exogenous signals from bacteria, viruses and parasites via recognition receptors, such as Toll-like receptors and immunoglobulins [4-6]. Mast cells are not only involved in first line defence against pathogens but also represent important mediators in diseases such as allergy and asthma, once they become dysregulated in response to an excess of allergen or allergen-specific IgE [5, 6]. Mast cells are laden with granules containing a wide variety of mediators, such as the proteases chymase, tryptase and the cathepsins, the vasoactive histamine, heparin and a plethora of cytokines such as Tumor Necrosis Factor α (TNFa), chemokines (e.g. Interleukin 8 (IL-8)) and other growth factors (e.g. Vascular Endothelial Growth Factor (VEGF), basic Fibroblast Growth Factor (bFGF)) [6].

Acute cardiovascular syndromes, such as myocardial infarction and vascular aneurysm formation, are still a major cause of death on the Western society. Atherosclerosis, one of the main cardiovascular disorders causing the acute cardiovascular events, is considered a chronic inflammatory disease, involving many inflammatory cells such as macrophages and T-lymphocytes [7, 8]. At later stages, when plaques become clinically manifest, thrombosis, coagulation and fibrinolysis will contribute to the escalation of the disease, which culminates in acute cardiovascular syndromes. Mast cells reside in the perivascular tissue of healthy arteries and during the progression of atherosclerosis, the cells accumulate in the adventitia and the shoulder region of the atherosclerotic plaque. Also the heart is one of the organs rich in mast cells. The whole array of mediators released by mast cells after its activation suggests that they could be involved in the development of atherosclerosis and vascular aneurysm formation, in which immune cells were demonstrated to play a central role. However, it remains to be elucidated whether mast cells are actively modulating the morphology of the arterial wall, thereby being instrumental in atherosclerotic plaque development and progression, aneurysm formation or causing plaque rupture.

In this review, we will outline present knowledge on the contribution of mast cells to cardiovascular diseases in general. Particular emphasis will be on the pathobiologies with an inflammatory component such as the development and progression of atherosclerosis, as well as to myocardial infarction and vascular aneurysm formation. Furthermore, we will discuss in vitro and in vivo models that have recently given more insight into the mechanisms by which mast cells exert their pathogenic effects. Finally, the therapeutic potential of modulation of mast cell function will be evaluated.

2. TECHNIQUES IN MAST CELL RESEARCH

Human pathology studies have provided ample evidence for the presence of a variety of immune and inflammatory cell types in diseased tissue and these studies have been essential in identifying the major cellular players in the progression of disease. Mast cells can easily be detected in tissue sections through a variety of mast cell staining protocols that are available at present. Toluidin Blue as well as a Chloro-Acetate Esterase (CAE) staining both stain the granulae of mast cells [9], while immunohistochemical analysis for CD117, tryptase or chymase can help to conclusively identify mast cell presence in tissues. Mucosal mast cells, present in e.g. lung and colon tissue and connective tissue type mast cells found in tissues like the perivascular tissue can be distinguished by an Alcian Blue/Saphranin O staining [10, 11].

*Address correspondence to this author at the Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC, Leiden, The Netherlands; Tel: +31-(0)71-5276213; Fax: +31-(0)71-5276032; E-mail: i.bot@lacdr.leidenuniv.nl
Animal models have greatly facilitated to understand the molecular mechanisms involved in cardiovascular diseases, be it atherosclerosis, ischemia/reperfusion injury, or aneurysm formation. In atherosclerosis, e.g. high fat diet fed rabbits and genetically modified hyperlipidemic mouse, such as the ApoE−/−, LDLr−/− or the ApoE3Leiden transgenic mice [15] have all been demonstrated to develop atherosclerotic plaques in aortic valve area, the aortic arch and carotid arteries and can be used for intervention studies. To induce myocardial infarction, coronary artery ligation models have been developed resulting in ischemia of the heart, often followed by reperfusion to study the inflammatory response [16, 17]. Likewise, a number of models have been described to identify key players in vascular aneurysm formation, which are generally based on elastase perfusion of the aorta [18], peri-aortic chemical injury [19], arterial clamping [20] or Angiotsin II infusion in atherosclerotic ApoE−/− mice [21].

Mast cell deficient animals were reported already in 1978, when Kitamura and colleagues first described W/Wv mice that were virtually devoid of tissue and skin mast cells [22]. These mice, besides being anemic, sterile and lack of hair pigmentation, were demonstrated to only have 1% of the normal number of skin mast cells compared to wild-type mice, while in other tissues of these mice mast cells are completely absent. W/Wv mice were found to carry a mutation in the C-Kit gene which results in an intrinsic defect in hematopoietic stem cells and dysregulated hematopoiesis. Injection of these mice with bone marrow from wild-type mice resulted in a repopulation of mast cells. The anemic Sl/Sld mouse has a comparable phenotype as the W/Wv mouse, however in this strain bone marrow transfer does not rescue the phenotype, suggesting that in these mice environmental factors needed to induce mast cell differentiation and maturation are absent [23, 24]. A mutation of the C-Kit gene in the white spotting (Ws) locus resulted in the mast cell deficient Ws/Ws rat [25]. More recently, a new mast cell deficient mouse was described that bears the spontaneously arisen W-sash (Wsb) inversion mutation. Unlike the previous two strains, mast cell deficiency is not accompanied by anemia and sterility [26]. These Kit(Wsb/Wsb) mice can also be repopulated with mast cells by injection of either bone marrow cells or cultured bone marrow derived mast cells (BMMCs), rendering this mouse a very interesting animal for studying mast cell biology in vivo.

Another approach in mast cell research, albeit not frequently pursued in cardiovascular disease models, involves systemic or focal mast cell activation in animals. To date, most research has been conducted in disease models of asthma, allergy and arthritis. Mast cells can be activated in various ways, of which IgE stimulation and hapten sensitization/challenge are widely known [27, 28]. Compound 48/80 is a well-known mast cell activator used in in vitro as well as in vivo studies [29]. In the next sections, human pathology studies as well as the use of in vitro and in vivo models investigating the role of mast cells and mast cell constituents in cardiovascular disorders will be described.

3. MAST CELLS IN ATHEROSCLEROSIS

Already in 1953, Constantinides reported that mast cells might be involved in the susceptibility to experimental atherosclerosis [30]. In this study, the author suggested that the heparin stored in mast cell granules could be atheroprotective. In a follow up study in 1954, Constantinides and co-workers stated that myocardial tissue from patients suffering from atherosclerosis displayed reduced numbers of mast cells per microscopic field compared to younger individuals not suffering from atherosclerosis [31]. As already demonstrated in his first report on experimental atherosclerosis, this phenomenon was again attributed to the atheroprotective role of mast cell derived heparin [30]. In the following decades, the paradigm gradually shifted towards a pro-atherogenic role for mast cells, as mast cell numbers in the intima, media as well as in the perivascular tissue (the adventitia), were in fact found to be increased with the progression of atherosclerosis [32].

Mast cell constituents such as histamine, prostaglandin D2 and leukotrienes play a role in atherogenesis and its clinical manifestations by affecting endothelial cell function and vasoreactivity. This hypothesis is strengthened by the recent finding that increased mast cell numbers in the adventitia of coronary arteries associate with vasospasms [33]. Chymase, a mast cell protease, can contribute to vasoconstriction by converting Angiotensin I into the vasoactive Angiotensin II (AngII), independently of Angiotensin-I Converting Enzyme (ACE) [34, 35]. Furthermore, chymase has been demonstrated to convert big endothelin-1 (ET-1) to 31-amino acid-length endothelins, ETs(1-31), which also act vasoconstrictive [36, 37].

Although mast cells were on one hand demonstrated to inhibit macrophage induced oxidation of Low Density Lipoprotein (LDL) [38, 39], mast cells have on the other hand been suggested to contribute to atherogenesis through secretion of heparin proteoglycans (HPG) containing granules, which in turn bind LDL. HPG bound LDL can subsequently be captured in the intima by phagocytosing macrophages, leading to enhanced lipid accumulation and lesion progression [40, 41]. Additionally, mast cell chymase is able to degrade apoE and apoAI, leading to a reduction of cholesterol efflux from macrophages to these apolipoproteins, which enhances foam cell formation [42]. Furthermore, oxidized LDL (OxLDL), modified in the intima, can induce mast cell degranulation, resulting in atherosclerotic lesion expansion through a self-amplifying cascade and moreover through increased leukocyte influx [43, 44]. Secretion of chemokines Monocyte Chemotactic Protein-1 (MCP-1) and IL-8 by mast cells will also increase leukocyte influx into the plaque [45]. Mast cell progenitors could be recruited to the plaque as well during plaque progression together with other pro-inflammatory cells such as monocytes and lymphocytes. Haley et al. described the presence of CCR3 positive mast cells in plaques of atherosclerotic arteries, while the primary ligand of CCR3, eotaxin, was demonstrated to be highly expressed by activated vascular smooth muscle cells [46], suggesting that the chemokine receptor CCR3 is involved in this process.

Foci of mast cell accumulation were detected in the intima at later stages of plaque formation, mainly near the shoulder region and in areas of early calcification of the plaque [47-50]. As described above, these mast cells may have been recruited to the plaque by chemokines such as...
eotaxin and adhere to the plaque surface or to extracellular matrix components such as fibronectin, vitronectin or laminin via integrins and adhesion molecules like intercellular adhesion molecule (ICAM)-1 [51]. In addition, mast cells may also be (co-)activated upon binding to extracellular matrix molecules, thereby releasing a variety of cytokines into its environment [52, 53].

Intimal mast cells have been demonstrated to contain tryptase, and approximately 40% of the cells contained chymase as well [50]. Both mast cell proteases were able to activate matrix metalloproteinases (MMPs) leading to degradation of collagen and elastin [54-56], consequently resulting in further destabilization of the plaque. As Kovanen and colleagues demonstrated, increased numbers of activated mast cells have been identified in particular in the adventitia of vulnerable and ruptured lesions in patients with myocardial infarction and more importantly, their number was found to correlate with the incidence of plaque rupture and erosion [57-59]. Both may lead to thrombus formation and eventually to acute coronary syndromes such as myocardial infarction. Mast cell activation has recently been demonstrated to have a potential role in the process of endothelial desquamation by demonstrating that the number of subendothelial mast cells correlated with the number of parietal microthrombi, which may have formed at sites of partial plaque erosion [60, 61].

It is not completely clear whether or not adventitial mast cells are capable of modulating intimal processes and instrumental in plaque rupture, although most evidence points in that direction. Pathology studies so far suggest that adventitial mast cells indeed contribute to plaque destabilization and plaque rupture, as mentioned above by release of mast cell proteases chymase and tryptase that can directly degrade matrix molecules themselves but also by activation of MMPs and by conversion of AngI into the proinflammatory, vasoactive AngII [62]. Secondly, mast cells were reported to induce apoptosis of cardiomyocytes [63], vascular smooth muscle cells [64-66] and endothelial cells [67, 68] in vitro, which could translate in reduced plaque stability [69, 70].

A third mechanism through which mast cells can contribute to plaque progression and destabilization is by enhancing neovascularization of the plaque. Indeed, in neovascularized areas of human coronary atheromas mast cells were demonstrated to colocalize with intraplaque microvessels [71]. In vitro studies showed endothelial proliferation in response to mitogenic factors. Conceivably, VEGF secreted by mast cells [72] could result in enhanced outgrowth of microvessels. Mast cells containing basic Fibroblast Growth Factor (bFGF), a potent angiogenic factor, were located near microvessels in the intima and adventitia of human coronary artery lesions [73], suggestive of a role of these mast cells in neo-angiogenesis. Furthermore, mast cells may, by releasing the vasoactive agent histamine, contribute to microvessel leakage and intraplaque hemorrhage [71].

Only recently, experimental proof was provided in support of a role of mast cells in atherosclerotic plaque development and progression. Sun et al. used the mast cell deficient Kit(W+/-)/W(W+/-) mice, which had been backcrossed with the atherosclerotic LDLr/− mouse [74]. Atherogenesis in the mast cell deficient LDLr/− mice was hampered compared to control LDLr/− mice. Importantly, lipid deposition, macrophage content and plaque apoptosis were reduced, while collagen content and fibrous cap development were increased in these mice, reflective of a more stable phenotype of mast cell deficient plaques. Repopulation of these mice with wild-type BMMCs completely reversed the beneficial effect of mast cell absence. Adoptive transfer of IL-6+ or IFNγ+ BMMCs did however not affect lesion progression, implying that mast cell-derived IL-6 and IFNγ are the prime factors in mast cell dependent plaque initiation. This elegant study conclusively demonstrates the contribution of mast cells to the progression of atherosclerosis, however left unanswered whether mast cells modulate the atherogenic response focally or alter the immune status of the mice, in particular as intimal mast cells are rather scarce in mouse plaques.

In a parallel study by us, we have pursued a different strategy to address the direct role of vascular mast cells. We have applied slightly constrictive perivascular silastic collars at the carotid arteries of apoE−/− mice to stimulate flow-induced atherosclerotic plaque formation [75]. After the development of advanced atherosclerotic plaques, we sensitized the mice and subsequently activated perivascular mast cells focally at the lesion site by adventitial application of a pluronic gel containing a hapten to induce mast cell activation. Focal mast cell activation in the perivascular tissue of advanced plaques sharply increased the incidence of intraplaque hemorrhage and macrophage apoptosis, the latter being both mast cell protease and histamine dependent [76]. Surprisingly, microvascular leakage was highly enhanced after mast cell activation, which might be responsible for the increased intraplaque bleeding. Furthermore, mast cell activation resulted in enhanced leukocyte recruitment to the plaque, which was CXCR2 and VLA-4-mediated. Most importantly, treatment with the mast cell stabilizer cromolyn prevented all of the undesirable phenomena elicited by mast cell activation, rendering mast cell stabilization a new therapeutic approach in the prevention of acute coronary syndromes.

Mast cell function in cardiovascular disease was recently shown to be in part dependent on galectin-3, which is a member of N-acetyllactosamine-binding lectin family expressed amongst others by mast cells [77]. Galectin-3−/−/apoE−/− showed an impaired atherogenic response as compared to apoE−/− mice, while plaques of galectin-3−/−apoE−/− mice had a lower number of perivascular inflammatory infiltrates and mast cells than those of apoE−/− mice [78].

The triggers that activate mast cells during lesion progression and plaque rupture are still subject to investigation. As described above, mast cells can be activated by modified LDL particles which concurs with the notion that bioactive phospholipid components might activate mast cells [43, 44], while mast cells have also been described to colocalize with nerve endings [58, 59, 79]. Interestingly, mast cells have previously been demonstrated to be activated by various neuropeptides [80, 81] and stress was seen to induce massive histamine release by mast cells [82]. The presence of neurons in the perivascular tissue in the vicinity of mast cells
and the plaque renders neuron-mediated mast cell activation a plausible mechanism in cardiovascular diseases.

4. MAST CELLS IN AORTIC VALVE STENOSIS

Aortic valve stenosis (AS) shares many features with atherosclerosis, including infiltration of inflammatory cells such as macrophages and T-lymphocytes, accumulation of oxidized lipids and extensive tissue remodeling [83, 84]. Analogous to atherosclerosis, also in the diseased aortic valve area mast cells were demonstrated to be abundantly present, as visualized by CD117 immunoreactivity and toluidin blue staining [85]. The molecular mechanisms of this pathological process still remains to be elucidated. A few years ago, AngII was suggested to contribute to the pathogenesis of aortic valve stenosis [86]. In this study, Angiotensin I Converting Enzyme (ACE) mRNA was demonstrated to be upregulated in the stenotic aortic valve and to co-localize with macrophages. Interestingly, also mRNA of chymase, which, as mentioned above, is an AngII producing enzyme as well, was significantly upregulated in these stenotic valve areas, while also the number of mast cells as well as the degree of degranulation was highly increased. Furthermore, cathepsin G co-localized with mast cells in these diseased regions [87]. Hence, current evidence suggests that mast cells are implicated in valve remodeling and AS progression as well, although more research is necessary to delineate the exact contribution of mast cells to this disease process.

5. MAST CELLS AND MYOCARDIAL INFARCTION

Myocardial infarction occurs mainly following rupture of an atherosclerotic plaque, leading to thrombus formation and vessel occlusion. The heart is a mast cell-rich organ and serum IgE levels were found to be significantly higher in the patients with unstable angina and acute myocardial compared to stable angina pectoris and controls, indicating that IgE might play a role in the pathogenesis of unstable angina pectoris and acute myocardial infarction [88]. Whole blood histamine levels from patients with stable coronary artery disease were elevated compared to control patients and was shown to be correlated to isoprostane levels as measure for oxidative stress [89], suggesting that histamine might be a risk factor in coronary events. Serum tryptase levels after myocardial infarction may also be altered, albeit that data are still subject to some controversy. Van Haelst et al. did not detect any differences in tryptase levels between patients with acute myocardial infarction, with unstable angina pectoris or controls that did not suffer from ischemic cardiovascular diseases [90]. These data have later been confirmed by Kervinen et al. [91]. On the other hand, Filipiak and colleagues found elevated serum tryptase levels in patients suffering from myocardial infarction with an ST-segment depression [92]. In fact tryptase levels were even reported to be an independent predictor for future coronary artery disease along with age [93].

In a guinea pig model of ischemia/reperfusion, histamine was demonstrated to be released after an ischemic period [94]. Mast cell distribution in the heart was investigated after induction of acute myocardial infarction in rats, showing a clear-cut accumulation of mast cells in the infarcted region of the heart [95]. Also in dogs, the number of mast cells was highly increased after induction of ischemia/reperfusion injury while macrophages in the infarcted myocardium were demonstrated to express Stem Cell Factor (SCF), a potent attractant for mast cells. This led the authors to suggest that mast cells are recruited by macrophage derived SCF [96]. Mast cell chymase was shown to be upregulated in the infarcted left ventricle in a hamster model of MI, while also the number of chymase-positive mast cells in that area was significantly higher than in the sham operated group. Chymase release could in turn result in enhanced AngII levels and indeed, treatment with an AngII type 1 receptor antagonist was seen to decrease mortality rates, while an ACE inhibitor was ineffective [97]. Apparently, AngII produced by mast cell derived chymase is involved in the pathophysiological state of the heart after MI. In support of this hypothesis, treatment of hamsters with specific chymase inhibitors (BCEAB, TEI-E548 and NK3201) improved cardiac function and mortality rate after the induction of MI [98-100]. Furthermore, chymase can also induce cardiomyocyte apoptosis in vitro [63] and in swines that underwent coronary microembolization, mast cell activation status in the ischemic area correlated with the percentage of apoptotic cardiomyocytes [101]. Treatment of these animals with the mast cell stabilizer tranilast resulted in a reduction of mast cell activation and cardiomyocyte apoptosis, suggesting that mast cells contribute to cardiomyocyte apoptosis.

In general, mast cells have been demonstrated to accumulate in the heart after MI, while the exact role of mast cells after the MI however has not completely been elucidated. Mast cells might on one hand enhance the injury by the release of matrix-degrading enzymes such as chymase and tryptase and of pro-inflammatory cytokines and chemokines resulting in accumulation of inflammatory leukocytes in the infarcted area. Also, mast cell activation may aggravate the injury by the induction of cardiomyocyte apoptosis. As a rich source of VEGF and bFGF however, mast cells may on the other hand contribute to the wound healing response and collateral formation after ischemia. Further research will contribute to our understanding of the actual role of mast cells in MI.

6. MAST CELLS IN AORTIC ANEURYSMS

Aortic aneurysm development is a chronic degenerative condition, which is characterized by weakening and dilation of the aortic wall that results in a life-threatening risk of rupture and is associated with the development of atherosclerosis [102]. The first study to report a causal relation between mast cell density in the aortic wall and aneurysm rupture dates already from 1981 [103], when Faleiro et al. showed a more pronounced presence of mast cells in arteries of the circle of Willis of patients that died of subarachnoid hemorrhage (SAH) after aneurysm rupture, although the number of patients included in this study was very limited. Besides a single case study of a patient that died of coronary artery dissection in which the perivascular tissue was demonstrated to contain a large eosinophil and mast cell infiltrate [104], hardly any studies reported on the contribution of mast cells to aneurysm development up to 1999. In that year, Ithara et al. [62] conclusively demonstrated that in aneurysmal tissue of human aortas the number of activated chymase and tryp-
tase positive mast cells was significantly higher compared to non-aneurysmal atherosclerotic tissue. Mast cell derived chymase, as mentioned before one of the mast cell proteases, can convert AngI into AngII independent of the classic renin-angiotensin system (RAS). Ang II in turn is a very important factor in the development of aneurysms and indeed, chymase and AngII converting enzyme (ACE) activity were both upregulated in aneurysmal aortas compared to control tissue [105, 106]. These findings were in part confirmed by Ejiri et al. [107] who demonstrated that in sections of thoracic aortic aneurysm (TAA) samples, chymase-positive mast cells accumulated in the pro-inflammatory regions of TAA tissue, suggestive of a causal relationship between the number of activated mast cells and aneurysm rupture. Furthermore, protein extracts prepared from aneurysm tissue were demonstrated to activate pro-matrix metalloproteinase-9 (MMP-9) into its active form [108], which was demonstrated to be inhibited by the chymase inhibitor NK3201, thereby defining yet another pathway by which chymase can contribute to aneurysm development. Tsuruda et al. [109] found an increased number of mast cells in abdominal aortic aneurysm (AAA) tissue as compared to atherosclerotic aortas without any aneurysmal change. These authors also showed high immunoreactivity of these mast cells for adrenomedullin (AM), which exerts antifibrotic actions in cardiovascular remodeling, thus resulting in a reduced stability of the vessel wall. In conclusion, although the number of human pathology studies on mast cells in aneurysm is limited and the sample sizes of most studies small, all evidence directs towards a causal relationship between mast cell numbers and the incidence of aneurysm formation.

In vivo studies on the role of mast cell biology in aneurysm formation have been focussed on the mast cell protease chymase as an AngII producing enzyme. Chymase was indeed demonstrated to be involved in aneurysm development in an animal model where AAA was induced by application of elastase onto the abdominal aorta of hamsters that were treated with the specific chymase inhibitor NK3201 [110]. The aortic diameter in the NK3201-treated group was significantly reduced compared to the control group, indicating that the chymase inhibitor prevented the development of AAA in this animal model. Similarly, NK3201 treatment of dogs in which AAA was induced by injecting elastase into the abdominal aorta, resulted in a reduced ratio of medial and total vessel area compared to controls [111]. Collectively these studies show that chymase inhibition may be a useful therapy for prevention of abdominal aortic aneurysms.

Recently, Sun et al. studied the role of mast cells itself rather than a specific mast cell constituent in an animal model of abdominal aortic aneurysm (AAA) formation, in which AAA was induced by elastase perfusion in mast cell deficient Kit(W−/−) mice and syngenic control mice [112]. In this study, the mast cell-deficient mice failed to develop AAA because of reduced aortic expansion and internal elastic lamina degradation, while conversely compound 48/80 induced mast cell activation in wild-type mice resulted even in enhanced AAA growth. Mast cell stabilization with cromolyn diminished AAA formation in wild-type mice and the authors demonstrated that mast cells participate in AAA formation by influencing angiogenesis, vSMC apoptosis, and matrix-degrading protease expression. Reconstitution of the Kit(W−/−) mice with BMMCs from wild-type or TNFa−/− mice caused susceptibility to AAA formation to be recovered while IL-6−/− or IFNy−/− BMMCs were ineffective.

Similarly, AAA were induced in mast cell-deficient mutant Ws/Ws rats by peri-aortic CaCl2 application, which resulted in a decreased diameter of abdominal aorta compared to the aortic diameter of wild-type rats [113]. In the wild-type rats, AAA formation was accompanied by accumulation of mast cells, T-lymphocytes, IFNy positive cells and by ac-

---

**Fig. (1).** Important mast cell mediators in acute cardiovascular diseases.
tivated MMP-2 and -9, which was inhibited in the mast cell deficient rats and interestingly, these phenomena could be inhibited by treatment with the mast cell stabilizer tranilast.

In conclusion, these studies demonstrate that mast cells may not only participate in AAA pathogenesis by inducing aortic SMC apoptosis and by releasing proteases like chymase and tryptase, but also have a role in the inflammatory response in aneurysm development.

**7. CONCLUSIONS AND THERAPEUTIC POTENTIAL**

Culminating evidence from pathology and experimental studies points to a key role for mast cells not only in a range of immune diseases but also in various cardiovascular disorders. Perivascular as well as intimal mast cells were seen to contribute substantially to the pathogenesis of atherosclerosis and plaque destabilization (Fig. 1). Mast cells promote lipid accumulation, matrix degradation, apoptosis, increase leukocyte influx into the plaque and enhance microvascular leakage, all resulting in a sharply increased risk of intraplaque hemorrhage, plaque destabilization and rupture. Second, mast cells contribute importantly to aneurysm formation by the release of chymase, while also mast cell IL-6 and IFNγ were seen to be involved. A role of mast cells in the response after acute myocardial infarction seems plausible but still awaits experimental support. Intervention studies in cardiovascular disease models so far (Table 1) have revealed a number of promising leads that target pathogenic mast cells per se (mast cell stabilizers) or mast cell constituents such as chymase, tryptase, histamine, IFNγ and IL6, which may have high therapeutic potential in the prevention of plaque rupture, aneurysm formation and possibly other cardiovascular disorders.

**ACKNOWLEDGMENT**

The authors are supported by grant 916.86.046 from the Netherlands Organization for Scientific Research (I. B.) and grant 2003T201 from the Netherlands Heart Foundation (E.B.). The authors belong to the European Vascular Genomics Network (http://www.evgn.org), a Network of Excellence supported by the European Community’s Sixth Framework Program for Research Priority 1 (Life Sciences, Genomics, and Biotechnology for Health; contract LSHM-CT-2003-503254).

**REFERENCES**

[1] Ehrlich P. Beiträge zur theorie und praxis der histologischen färbung. Thesis, Leipzig University. 1878.
[2] Ehrlich P. Beiträge zur Kenntniss der Anilinfärbungen und ihrer Verwendung in der mikroskopischen Technik. Arch Mikr Anat 1877; 13: 263.
[3] Vyas H, Krishnaswamy G. Paul Ehrlich’s "Mastzellen"--from aniline dyes to DNA chip arrays: a historical review of developments in mast cell research. Methods Mol Biol 2006; 315: 3-11.
[4] Kelly JL, Chi DS, Abou-Auda W, Smith JK, Krishnaswamy G. The molecular role of mast cells in atherosclerotic cardiovascular disease. Mol Med Today 2000; 6: 304-8.
[5] Galli SJ, Kalesnikoff J, Grimalde MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-86.
[6] Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods Mol Biol 2006; 315: 13-34.
[7] Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
[8] Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
[9] Shukla SA, Veerappan R, Whittimore JS, Ellen Miller L, Youngberg GA. Mast cell ultrastructure and staining in tissue. Methods Mol Biol 2006; 315: 63-76.
[10] Nakano, T, Sonoda T, Hayashi C, et al. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal,
and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med 1985; 162:1025-43.

[11] Bienenstock J, Befus AD, Pearce F, Denburg J, Goodacre R. Mast cell heterogeneity: derivation of mast cells, with emphasis on the intestine. J Allergy Clin Immunol 1982; 70:477-12.

[12] Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71:343-53.

[13] Zhang SH, Reddick RL, Piedraja JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468-71.

[14] Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenosine-mediated gene delivery. J Clin Invest 1993; 92:883-93.

[15] van den Maagdenberg AM, Hofker MH, Krumpert PJ, et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993; 268:10540-5.

[16] Michael LH, Entman ML, Hartley CJ, et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol 1995; 269:H1247-54.

[17] Chimenti S, Carlo E, Masson S, Bai A, Latini R. Myocardial infarction: animal models. Methods Mol Med 2004; 98:217-26.

[18] Anjdar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental atheromas in rats. Circulation 1990; 82:973-81.

[19] Gertz SD, Kurgan A, Eisenberg D. Aneurysm of the rabbit carotid artery: an animal model. Am J Pathol 1995; 114:1483.

[20] Galli SJ, Miyamoto S, Mizoguchi A, Kume N, Kita T, Hashimoto N. Mouse model of cerebral aneurysm: experimental induction by renal hypertension and local hemodynamic changes. Stroke 2002; 33:1911-5.

[21] Daugherty A, Manning MW, Cassis LA. Angiostatin II promotes atherosclerotic lesions and atheromas in apolipoprotein E-deficient mice. J Clin Invest 2000; 105:1605-12.

[22] Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978; 52:447-52.

[23] Kitamura Y, Go S. Decreased production of mast cells in Sl/Sld anemic mice. Blood 1979; 53:492-7.

[24] Galli SJ, Kitamura Y. Genetically mast-cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo. Am J Pathol 1987; 127:191-98.

[25] Niwa Y, Kasugai T, Ohno K, et al. Anemia and mast cell depletion in mutant rats that are homozygous at “white spotting (Ws)” locus. J Pathol 1998; 185:10

[26] Kranenveld AD, Buckley TL, van Heuven-Nolsen D, van Schaik Y, Koster AS, Nijkamp FP. Delayed-type hypersensitivity-induced increase in vascular permeability in the mouse small intestine: inhibition by depletion of sensory neuropeptides and NK1 receptor blockade. Br J Pharmacol 1995; 114:1483-89.

[27] Hessel EM, van Oosterhout AJM, Hostra CL, et al. Bronchocstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice. Eur J Pharmacol 1995; 293:401-12.

[28] Mousli M, Hugli TE, Landry Y, Bronner C. Peptide/growth in human skin and rat peritoneal mast cell activation. Immunopharmacology 1994; 27:1-11.

[29] Constantines P. Mast cells and susceptibility to experimental atherosclerosis. Science 1953; 117:505-6.

[30] Cairns A, Constantines P. Mast cells in human atherosclerosis. Science 1954; 120:31-2.

[31] Adkinson JB, Harlan CW, Harlan GC, Virmani R. The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. Hum Pathol 1994; 25:154-9.

[32] Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ 2nd, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985; 313:1138-41.

[33] Takai S, Shiota N, Jin D, Miyazaki M. Functional role of chymase in angiostatin II formation in human vascular tissue. J Cardiovasc Pharmacol 1998; 32:826-33.

[34] Richard V, Hurel-Merle S, Sellart E, et al. Functional evidence for a role of vascular chymase in the production of angiostatin II in isolated human aorta and human aortic tissue culture function, with emphasis on the intestine. J Allergy Clin Immunol 1982; 70:477-12.

[35] Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y. Kido H. Selective conversion of big endotoxins to thromboxane smooth muscle-constricting 31-aminol-lactone endotoxins by chymase from human mast cells. J Immunol 1997; 159:1897-92.

[36] Maguire JJ, Kuc RE, Davenport AP. Vasoconstrictor activity of novel endothelin peptide, ET-1(1-31), in human mammary and coronary arteries. Br J Pharmacol 2001; 134:1360-6.

[37] Lindstedt KA, Kokkonen JO, Kovanen PT. Inhibition of copper-mediated oxidation of LDL by rat serumal mast cells. A novel cellular protective mechanism involving proteolysis of the substrate under oxidative stress. Arterioscler Thromb 1993; 13:23-32.

[38] Lindstedt KA. Inhibition of macrophage-mediated low density lipoprotein oxidation by stimulated rat serumal mast cells. J Biol Chem 1993; 268:7741-6.

[39] Paananen K, Kovanen PT. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules. J Biol Chem 1994; 269:2023-31.

[40] Kaatrinen M, Penttilä A, Kovanen PT. Extracellular mast cell granules that carry apoE-mediated B-100-containing lipoproteins into phagocytes in human arterial intima. Functional coupling of exocytosis and phagocytosis in neighbouring cells. Arterioscler Thromb Vasc Biol 1995; 15:2047-54.

[41] Lee M, Calabresi L, Chiesa G, Franceschini G, Kovanen PT. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholest erol efflux. Arterioscler Thromb Vasc Biol 2002; 32:1475-81.

[42] Liao L, Granger DN. Role of mast cells in oxidized low-density lipoprotein-induced microvascular dysfunction. Am J Physiol 1996; 271:H1795-800.

[43] Liao L, Starzyk RM, Granger DN. Molecular determinants of oxidized low-density lipoprotein-induced leukocyte adhesion and microvascular dysfunction. Arterioscler Thromb Vasc Biol 1997; 17:437-44.

[44] Kinoshita M, Okada M, Hara M, Furukawa Y, Matsumori A. Mast cell tryptase in mast cell granules enhances MCP-1 and interleukin-8 production in human endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25:1858-63.

[45] Haley KJ, Lilly CM, Yang JH, et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 2000; 102:2185-9.

[46] Jeziorska M, McCollum C, Woolley DE. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J Pathol 1987; 152:115-22.

[47] Jeziorska M, McCollum C, Woolley DE. Calcification in atherosclerotic plaque of human carotid arteries: associations with mast cells and macrophages. J Pathol 1998; 185:10-7.

[48] Kaatrinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90:1690-78.

[49] Kaatrinen M, Penttilä A, Kovanen PT. Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler Thromb 1994; 14:966-72.

[50] Okayama Y. Mast cell matrix interactions. Clin Exp Allergy 2000; 30:455-7.

[51] Oki T, Kitaura J, Eto K, et al. Integrin alphabeta3 promotes the adhesion and activation of mast cells through interaction with fibronectin. J Immunol 2006; 176:52-60.

[52] Krüger-Krasagakes S, Grützka A, Krasagakis K, Hoffmann S, Jazbec BM. Adhesion of human mast cells to extracellular matrix provides a co-stimulatory signal for cytokine production. Immunology 1999; 98:253-7.

[53] Lees M, Taylor DJ, Woolley DE. Mast cell proteases activate precursor of collagenase and stromelysin but not of gelatinases A and B. Eur J Biochem 1994; 223:171-77.
Mast Cells: Pivotal Players in Cardiovascular Diseases

Deficient mice. von der Thusen JH, van Berkel TJC, Biessen EAL. 13 sclerosis by releasing proinflammatory cytokines. Nat Med 2007; 1: 2516-25.

K. Chaludakov GN, Fiore M, Stankulov IS, et al. NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arterioscler Thromb Vasc Biol 2007; 1: 109-14.

M. Mortiyama M, Sato T, Inoue H, et al. The neuropeptide neumodin U promotes inflammation by direct activation of mast cells. J Exp Med 2005; 2: 217-24.

F. Ferry X, Brehin S, Kamel R, Landry Y. G protein-dependent activation of mast cell by peptides and basic secretagogues. Peptides 2002; 23: 1507-15.

H. Huang M, Pang X, Lotourneu R, Boucher W, Theohairides TC. Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in Apolipoprotein E knockout mice. Cardiovasc Res 2002; 55: 150-60.

O. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis: histological and immunohistochemical studies. Circulation 1994; 90: 844-53.

O. Olsson M, Thyberg J, Nilsson P. Presence of oxidized low-density lipoprotein in nonstenotic aortic valve. Arterioscler Thromb Vasc Biol 1999; 19: 1218-22.

V. Veinot JP, Prichett-Pejic W, Song J, et al. CD117-positive cells and mast cells in adult human cardiac valves—observations and implications for the creation of bioengineered grafts. Cardiovasc Pathol 2006; 15: 36-40.

H. Helske S, Lindstedt KA, Laine M, et al. Induction of local angiogenesis II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004; 44: 1859-66.

H. Helske S, Syvänta S, Kupari M, et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 2006; 27: 1495-1504.

K. Korkmaz ME, Otto A, Saracalar Y, et al. Levels of IgE in the serum of patients with coronary arterial disease. Int J Cardiol 1991; 31: 199-204.

S. Clejan S, Japa S, Clemensc J, Hasahni S, David O, Talano JV. Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis. J Cell Mol Med 2002; 6: 583-92.

V. van Haelst PL, Timmer JR, Crijns HJ, Kauffkin HF, Gans RO, van Doormaal JJ. No long-lasting or intermittent mast cell activation in acute coronary syndromes. Int J Cardiol 2001; 78: 75-80.

B. Jawaid S, Milot G, Haan M, Haylett P, Mántrari M, Kovámen PT. Serum tryptase levels in acute coronary syndromes. Int J Cardiol 2005; 104: 138-43.

F. Filipiak KJ, Tarchalska-Kryniska B, Opolski G, et al. Tryptase levels in patients after acute coronary syndromes: the potential new marker of an unstable plaque? Clin Cardiol 2003; 26: 366-72.

D. Delargyris EN, Upadhyya B, Sane DC, et al. Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. Atherosclerosis 2005; 178: 381-6.

G. Masini E, Giannella E, Bianchi S, Manniòni PF, Histamine and lactate dehydrogenase (LDH) release in ischemic myocardium of the guinea-pig. Agents Actions 1987; 20: 281-3.

G. Engels W, Reiters PH, Daemen MJ, Smits JF, van der Vusse GJ. Transmural changes in mast cell density in rat heart after infarct induction in vivo. J Pathol 1995; 177: 423-9.

F. Frangogiannis NG, Perrad JL, Mendoza LH, et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 1998; 98: 687-98.

J. Jin D, Takai S, Yamada M, Sakaguchi M, Yao Y, Miyazaki M. Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol 2001; 86: 203-14.

J. Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M. Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci 2002; 71: 437-46.
[99] Hoshino F, Urata H, Inoue Y, et al. Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 2003; 41 Suppl 1: S11-8.

[100] Jin D, Takai S, Yamada M, et al. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res 2003; 60: 413-20.

[101] Zhang QY, Ge JB, Chen JZ, et al. Mast cell contributes to cardiomyocyte apoptosis after coronary microembolization. J Histochem Cytochem 2006; 54: 515-23.

[102] Thompson RW. Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. Curr Opin Cardiol 1996; 11: 504-18.

[103] Faleiro LC, Machado CR, Gripp A Jr, Resende RA, Rodrigues PA. Cerebral vasospasm: presence of mast cells in human cerebral arteries after aneurysm rupture. J Neurosurg 1981; 54: 733-5.

[104] Saunders SL, Ford SE. Primary coronary artery dissection possibly related to drug hypersensitivity in a male. Can J Cardiol 1991; 7: 138-40.

[105] Nishimoto M, Takai S, Fukamoto H, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci 2002; 71: 2195-205.

[106] Tsunemi K, Takai S, Nishimoto M, et al. Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta. Hypertens Res 2002; 25: 817-22.

[107] Ejiri J, Inoue N, Tsukube T, et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003; 59: 988-96.

[108] Furubayashi K, Takai S, Jin D, et al. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta 2008; 388: 214-6.

[109] Tsuruda T, Kato J, Hatakeyama K, et al. Adrenomedullin in mast cells of abdominal aortic aneurysm. Cardiovasc Res 2006; 70: 158-64.

[110] Tsunemi K, Takai S, Nishimoto M, et al. A specific chymase inhibitor, 2-[5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl]-N-[(3,4-dioxo-1-phenyl-7-(2-pyridyloxy)-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 2004; 309: 879-83.

[111] Furubayashi K, Takai S, Jin D, et al. The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens Res 2007; 30: 349-57.

[112] Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007; 117: 3359-68.

[113] Tsuruda T, Kato J, Hatakeyama K, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008; [Epub ahead of print].